No Data
No Data
WHO and WEF Are Pushing AI in Global Healthcare -- What It Means for the Market
Express News | BioXcel Therapeutics Inc: May Offer and Sell Shares of Common Stock of up to $8.1 Mln From Time to Time Through Canaccord - SEC Filing
BofA Securities Maintains BioXcel Therapeutics(BTAI.US) With Sell Rating, Cuts Target Price to $1
BioXcel Therapeutics Advances Clinical Trials and Reduces Losses
BioXcel Therapeutics | 10-K: FY2024 Annual Report
BioXcel Therapeutics Price Target Lowered to $1 From $4 at BofA